These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11773089)

  • 21. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.
    García-Lerma JG; Heneine W
    J Clin Virol; 2001 Jun; 21(3):197-212. PubMed ID: 11397656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.
    Sarmati L; Nicastri E; Parisi SG; d'Ettorre G; Mancino G; Narciso P; Vullo V; Andreoni M
    J Clin Microbiol; 2002 Feb; 40(2):335-40. PubMed ID: 11825939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.
    Parkin NT; Hellmann NS; Whitcomb JM; Kiss L; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2004 Feb; 48(2):437-43. PubMed ID: 14742192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.
    Agwale SM; Zeh C; Paxinos E; Odama L; Pienazek D; Wambebe C; Kalish ML; Ziermann R
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):22-6. PubMed ID: 16438641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
    Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Åsjö B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stöckl E; Sönnerborg A; Staneková D; Stanojevic M; Van Laethem K; Zazzi M; Zidovec Lepej S; Boucher CAB; Schmit JC; Wensing AMJ; ; Puchhammer-Stockl E; Sarcletti M; Schmied B; Geit M; Balluch G; Vandamme AM; Vercauteren J; Derdelinckx I; Sasse A; Bogaert M; Ceunen H; De Roo A; De Wit S; Echahidi F; Fransen K; Goffard JC; Goubau P; Goudeseune E; Yombi JC; Lacor P; Liesnard C; Moutschen M; Pierard D; Rens R; Schrooten Y; Vaira D; Vandekerckhove LPR; Van den Heuvel A; Van Der Gucht B; Van Ranst M; Van Wijngaerden E; Vandercam B; Vekemans M; Verhofstede C; Clumeck N; Van Laethem K; Beshkov D; Alexiev I; Lepej SZ; Begovac J; Kostrikis L; Demetriades I; Kousiappa I; Demetriou V; Hezka J; Linka M; Maly M; Machala L; Nielsen C; Jørgensen LB; Gerstoft J; Mathiesen L; Pedersen C; Nielsen H; Laursen A; Kvinesdal B; Liitsola K; Ristola M; Suni J; Sutinen J; Descamps D; Assoumou L; Castor G; Grude M; Flandre P; Storto A; Hamouda O; Kücherer C; Berg T; Braun P; Poggensee G; Däumer M; Eberle J; Heiken H; Kaiser R; Knechten H; Korn K; Müller H; Neifer S; Schmidt B; Walter H; Gunsenheimer-Bartmeyer B; Harrer T; Paraskevis D; Hatzakis A; Zavitsanou A; Vassilakis A; Lazanas M; Chini M; Lioni A; Sakka V; Kourkounti S; Paparizos V; Antoniadou A; Papadopoulos A; Poulakou G; Katsarolis I; Protopapas K; Chryssos G; Drimis S; Gargalianos P; Xylomenos G; Lourida G; Psichogiou M; Daikos GL; Sipsas NV; Kontos A; Gamaletsou MN; Koratzanis G; Sambatakou H; Mariolis H; Skoutelis A; Papastamopoulos V; Georgiou O; Panagopoulos P; Maltezos E; Coughlan S; De Gascun C; Byrne C; Duffy M; Bergin C; Reidy D; Farrell G; Lambert J; O'Connor E; Rochford A; Low J; Coakely P; O'Dea S; Hall W; Mor O; Levi I; Chemtob D; Grossman Z; Zazzi M; de Luca A; Balotta C; Riva C; Mussini C; Caramma I; Capetti A; Colombo MC; Rossi C; Prati F; Tramuto F; Vitale F; Ciccozzi M; Angarano G; Rezza G; Kolupajeva T; Vasins O; Griskevicius A; Lipnickiene V; Schmit JC; Struck D; Sauvageot N; Hemmer R; Arendt V; Michaux C; Staub T; Sequin-Devaux C; Wensing AMJ; Boucher CAB; van de Vijver DAMC; van Kessel A; van Bentum PHM; Brinkman K; Connell BJ; van der Ende ME; Hoepelman IM; van Kasteren M; Kuipers M; Langebeek N; Richter C; Santegoets RMWJ; Schrijnders-Gudde L; Schuurman R; van de Ven BJM; Åsjö B; Kran AB; Ormaasen V; Aavitsland P; Horban A; Stanczak JJ; Stanczak GP; Firlag-Burkacka E; Wiercinska-Drapalo A; Jablonowska E; Maolepsza E; Leszczyszyn-Pynka M; Szata W; Camacho R; Palma C; Borges F; Paixão T; Duque V; Araújo F; Otelea D; Paraschiv S; Tudor AM; Cernat R; Chiriac C; Dumitrescu F; Prisecariu LJ; Stanojevic M; Jevtovic D; Salemovic D; Stanekova D; Habekova M; Chabadová Z; Drobkova T; Bukovinova P; Shunnar A; Truska P; Poljak M; Lunar M; Babic D; Tomazic J; Vidmar L; Vovko T; Karner P; Garcia F; Paredes R; Monge S; Moreno S; Del Amo J; Asensi V; Sirvent JL; de Mendoza C; Delgado R; Gutiérrez F; Berenguer J; Garcia-Bujalance S; Stella N; de Los Santos I; Blanco JR; Dalmau D; Rivero M; Segura F; Elías MJP; Alvarez M; Chueca N; Rodríguez-Martín C; Vidal C; Palomares JC; Viciana I; Viciana P; Cordoba J; Aguilera A; Domingo P; Galindo MJ; Miralles C; Del Pozo MA; Ribera E; Iribarren JA; Ruiz L; de la Torre J; Vidal F; Clotet B; Albert J; Heidarian A; Aperia-Peipke K; Axelsson M; Mild M; Karlsson A; Sönnerborg A; Thalme A; Navér L; Bratt G; Karlsson A; Blaxhult A; Gisslén M; Svennerholm B; Bergbrant I; Björkman P; Säll C; Mellgren Å; Lindholm A; Kuylenstierna N; Montelius R; Azimi F; Johansson B; Carlsson M; Johansson E; Ljungberg B; Ekvall H; Strand A; Mäkitalo S; Öberg S; Holmblad P; Höfer M; Holmberg H; Josefson P; Ryding U
    Clin Infect Dis; 2016 Mar; 62(5):655-663. PubMed ID: 26620652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
    Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
    J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
    Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
    J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups.
    Tuaillon E; Gueudin M; Lemée V; Gueit I; Roques P; Corrigan GE; Plantier JC; Simon F; Braun J
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1543-9. PubMed ID: 15577405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
    Borroto-Esoda K; Parkin N; Miller MD
    Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time trends in primary HIV-1 drug resistance among recently infected persons.
    Grant RM; Hecht FM; Warmerdam M; Liu L; Liegler T; Petropoulos CJ; Hellmann NS; Chesney M; Busch MP; Kahn JO
    JAMA; 2002 Jul; 288(2):181-8. PubMed ID: 12095382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.